{"content":"<li class=\"n-box-item date-title\" data-end=\"1484974799\" data-start=\"1484888400\" data-txt=\"Sunday, December 22, 2019\">Friday, January 20, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3236538\" data-ts=\"1484955531\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/P\" target=\"_blank\">P</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3236538-after-hours-volume-on-pandora-media-up-2_3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After-hours volume on Pandora Media, up 2.3%</a></h4><ul>   <li>Pandora Media (NYSE:<a href='https://seekingalpha.com/symbol/P' title='Pandora Media'>P</a>) has made a run after hours on some not-insignificant share volume.</li>    <li>Shares are trading <font color='green'>up 2.3%</font> at $13.55, which would match its highest point intraday since Dec. 20.</li>    <li>That's on more than 1.7M shares traded in the post-session, more than a quarter average daily volume.</li>    <li>The after-hours quote has inched within 10% of the stock's 52-week high, reached Sept. 7.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3236538\" data-linked=\"After-hours volume on Pandora Media, up 2.3%\" data-tweet=\"$P - After-hours volume on Pandora Media, up 2.3% https://seekingalpha.com/news/3236538-after-hours-volume-on-pandora-media-up-2_3?source=tweet\" data-url=\"https://seekingalpha.com/news/3236538-after-hours-volume-on-pandora-media-up-2_3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:38 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3236530\" data-ts=\"1484951727\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3236530-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/HMY' title='Harmony Gold Mining Company Limited'>HMY</a> <font color='green'>+4.0%</font>. <a href='https://seekingalpha.com/symbol/RAD' title='Rite Aid Corporation'>RAD</a> <font color='green'>+3.9%</font>. <a href='https://seekingalpha.com/symbol/P' title='Pandora Media'>P</a> <font color='green'>+3.7%</font>. <a href='https://seekingalpha.com/symbol/WNC' title='Wabash National Corporation'>WNC</a> <font color='green'>+2.6%</font>. <a href='https://seekingalpha.com/symbol/TVTY' title='Tivity Health, Inc.'>TVTY</a> <font color='green'>+2.5%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/IMMU' title='Immunomedics, Inc.'>IMMU</a> <font color='red'>-6.5%</font>. <a href='https://seekingalpha.com/symbol/RCII' title='Rent-A-Center Inc.'>RCII</a> <font color='red'>-5.0%</font>. <a href='https://seekingalpha.com/symbol/OSG' title='Overseas Shipholding Group, Inc.'>OSG</a> <font color='red'>-4.5%</font>. <a href='https://seekingalpha.com/symbol/TSQ' title='Townsquare Media'>TSQ</a> <font color='red'>-2.1%</font>. <a href='https://seekingalpha.com/symbol/LOXO' title='Loxo Oncology'>LOXO</a> <font color='red'>-1.8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3236530\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$HMY $RAD $P - After Hours Gainers / Losers https://seekingalpha.com/news/3236530-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3236530-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3236526\" data-ts=\"1484950211\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DISH\" target=\"_blank\">DISH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3236526-jury-penalizes-dish-network-20_5m-for-telemarketing-calls\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jury penalizes Dish Network $20.5M for telemarketing calls</a></h4><ul>   <li>A North Carolina jury has handed down a <a href=\"http://www.heraldsun.com/business/jury-finds-dish-network-liable-in-m-case-bahama-s/article_163c6836-df5b-11e6-bc5c-4f240781a71a.html\" target=\"_blank\">$20.5M verdict against Dish Network</a> (<a href='https://seekingalpha.com/symbol/DISH' title='DISH Network Corporation'>DISH</a> <font color='red'>-2.5%</font>), finding the company liable for more than 51,000 telemarketing calls to numbers on the nation's Do Not Call Registry.</li>    <li>That comes to $400 per violation; the jury had the option of awarding anywhere from $0 to $500 per violation.</li>    <li>Dish says it's evaluating legal options. The calls were placed by a now-defunct dealer.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3236526\" data-linked=\"Jury penalizes Dish Network $20.5M for telemarketing calls\" data-tweet=\"$DISH - Jury penalizes Dish Network $20.5M for telemarketing calls https://seekingalpha.com/news/3236526-jury-penalizes-dish-network-20_5m-for-telemarketing-calls?source=tweet\" data-url=\"https://seekingalpha.com/news/3236526-jury-penalizes-dish-network-20_5m-for-telemarketing-calls\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3236520\" data-ts=\"1484949293\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3236520-weekly-etf-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Weekly ETF Gainers / Losers</a></h4><ul>     <li><b>Top gainers:</b> <a href='https://seekingalpha.com/symbol/BRF' title='VanEck Vectors Brazil Small-Cap ETF'>BRF</a> <font color='green'>+2.9%</font>. <a href='https://seekingalpha.com/symbol/EWZ' title='iShares MSCI Brazil Capped ETF'>EWZ</a> <font color='green'>+2.1%</font>. <a href='https://seekingalpha.com/symbol/XLP' title='Consumer Staples Select Sector SPDR ETF'>XLP</a> <font color='green'>+2.1%</font>. <a href='https://seekingalpha.com/symbol/PSLV' title='Sprott Physical Silver Trust'>PSLV</a> <font color='green'>+2.1%</font>. <a href='https://seekingalpha.com/symbol/ILF' title='iShares Latin America 40 ETF'>ILF</a> <font color='green'>+1.9%</font>.</li>     <li><b>Top losers:</b> <a href='https://seekingalpha.com/symbol/URA' title='Global X Uranium ETF'>URA</a> <font color='red'>-5.4%</font>. <a href='https://seekingalpha.com/symbol/UNG' title='The United States Natural Gas ETF, LP'>UNG</a> <font color='red'>-5.4%</font>. <a href='https://seekingalpha.com/symbol/GAZ' title='iPath DJ-UBS Natural Gas Total Return Sub-Index ETN'>GAZ</a> <font color='red'>-4.8%</font>. <a href='https://seekingalpha.com/symbol/VXX' title='iPath S&P 500 VIX Short-Term Futures ETN'>VXX</a> <font color='red'>-3.4%</font>. <a href='https://seekingalpha.com/symbol/KOL' title='VanEck Vectors Coal ETF'>KOL</a> <font color='red'>-2.3%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3236520\" data-linked=\"Weekly ETF Gainers / Losers\" data-tweet=\"$BRF $EWZ $XLP - Weekly ETF Gainers / Losers https://seekingalpha.com/news/3236520-weekly-etf-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3236520-weekly-etf-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:54 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3236518\" data-ts=\"1484948276\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BMY\" target=\"_blank\">BMY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3236518-merck-settles-keytruda-patent-fight-bristol-myers-and-ono-pharma-agrees-to-pay-625m-plus\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Merck settles Keytruda patent fight with Bristol-Myers and Ono Pharma, agrees to pay $625M plus royalties</a></h4><ul><li>Bristol-Myers Squibb (NYSE:<a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a>) and Ono Pharmaceutical Company, Ltd. reach a <a href=\"https://seekingalpha.com/pr/16719397-bristol-myers-squibb-ono-pharmaceutical-company-enter-settlement-license-agreement-merck\" target=\"_blank\">global patent settlement</a> with Merck (NYSE:<a href='https://seekingalpha.com/symbol/MRK' title='Merck & Co Inc.'>MRK</a>) related to cancer med Keytruda (pembrolizumab). BMY and Ono claimed that Keytruda, a PD-1 antibody, infringed on their patents related to the use of PD-1 antibodies [BMY's is Opdivo (nivolumb)] to treat cancer in the U.S., Europe, Australia and Japan.</li><li>Under the terms of the settlement, Merck will make an initial payment of $625M to BMY and Ono and pay a 6.5% royalty on Keytruda sales from January 1 of this year through the end of 2023 followed a 2.5% royalty from January 1, 2024 through 2026. BMY and Ono will share the royalties on a 75/25 basis, respectively.</li><li>The companies have also granted each other certain rights under their respective patent portfolios related to PD-1.</li><li>Inhibiting PD-1, an immune system checkpoint, enhances the immune system's anti-tumor response. Opdivo was the first such antibody to receive regulatory approval anywhere in the world.</li><li>BMY is up a fraction after hours while MRK is unchanged.</li></ul><div class=\"tiny-share-widget\" data-id=\"3236518\" data-linked=\"Merck settles Keytruda patent fight with Bristol-Myers and Ono Pharma, agrees to pay $625M plus royalties\" data-tweet=\"$BMY $BMY $MRK - Merck settles Keytruda patent fight with Bristol-Myers and Ono Pharma, agrees to pay $625M plus royalties https://seekingalpha.com/news/3236518-merck-settles-keytruda-patent-fight-bristol-myers-and-ono-pharma-agrees-to-pay-625m-plus?source=tweet\" data-url=\"https://seekingalpha.com/news/3236518-merck-settles-keytruda-patent-fight-bristol-myers-and-ono-pharma-agrees-to-pay-625m-plus\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>28&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3236495\" data-ts=\"1484945879\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAPL\" target=\"_blank\">AAPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3236495-qualcomm-sued-apple-over-patent-royalty-tactics\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Qualcomm sued by Apple over patent royalty tactics</a></h4><ul><li><a href=\"http://www.cnbc.com/2017/01/20/apple-sues-qualcomm-for-1-billion.html\" target=\"_blank\">Apple</a>&nbsp;(<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a> <font color='green'>+0.2%</font>): \"For many years Qualcomm has unfairly insisted on charging royalties for technologies they have nothing to do with. The more Apple innovates with unique features such as TouchID, advanced displays, and cameras, to name just a few, the more money Qualcomm collects for no reason and the more expensive it becomes for Apple to fund these innovations. Qualcomm built its business on older, legacy, standards but reinforces its dominance through exclusionary tactics and excessive royalties. Despite being just one of over a dozen companies who contributed to basic cellular standards, Qualcomm insists on charging Apple at least five times more in payments than all the other cellular patent licensors we have agreements with combined.\"</li><li>Apple further alleges Qualcomm has withheld $1B in payments as retaliatory measure \"for responding truthfully\" to law enforcement agency investigation into the company.</li><li>Earlier this week (January 17, 2017): <a href=\"https://seekingalpha.com/news/3235617-qualcomm-charged-ftc-anticompetitive-sales-licensing-tactics\" target=\"_blank\">Qualcomm charged by FTC over anticompetitive sales and licensing tactics</a></li><li>Qualcomm (NASDAQ:<a href='https://seekingalpha.com/symbol/QCOM' title='Qualcomm Inc.'>QCOM</a>)&nbsp;<font color='red'>-2.20%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3236495\" data-linked=\"Qualcomm sued by Apple over patent royalty tactics\" data-tweet=\"$AAPL $AAPL $QCOM - Qualcomm sued by Apple over patent royalty tactics https://seekingalpha.com/news/3236495-qualcomm-sued-apple-over-patent-royalty-tactics?source=tweet\" data-url=\"https://seekingalpha.com/news/3236495-qualcomm-sued-apple-over-patent-royalty-tactics\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>121&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3236499\" data-ts=\"1484945840\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CSX\" target=\"_blank\">CSX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3236499-csx-downgraded-deutsche-bank-after-yesterdays-gap-higher\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CSX downgraded at Deutsche Bank after yesterday&#39;s gap higher</a></h4><ul><li>CSX (<a href='https://seekingalpha.com/symbol/CSX' title='CSX Corporation'>CSX</a> <font color='red'>-2.6%</font>) is <a href=\"http://www.cnbc.com/2017/01/20/deutsche-bank-downgrades-csx-tells-clients-to-avoid-chasing-this-weeks-rally.html\" target=\"_blank\">downgraded</a> to Hold from Buy with a $42 price target at Deutsche Bank, which says investors should avoid <a href=\"https://seekingalpha.com/news/3236203-csx-board-says-will-discuss-strategy-harrison-mantle-ridge\" target=\"_blank\">chasing the rally</a> in the  stock sparked by a potential shake-up from activist investors.</li><li>The firm notes that shares are within 10% of its unchanged target price following  yesterday's 23% gap up, and more importantly within 5% of its \"blue sky\" scenario.</li><li>While CSX is well positioned, Deutsche Bank believes relative value considerations favor Union Pacific (<a href='https://seekingalpha.com/symbol/UNP' title='Union Pacific Corporation'>UNP</a> <font color='green'>+2.2%</font>) and Norfolk Southern (<a href='https://seekingalpha.com/symbol/NSC' title='Norfolk Southern Corporation'>NSC</a> <font color='red'>-0.6%</font>).</li></ul><div class=\"tiny-share-widget\" data-id=\"3236499\" data-linked=\"CSX downgraded at Deutsche Bank after yesterday&#39;s gap higher\" data-tweet=\"$CSX $CSX $UNP - CSX downgraded at Deutsche Bank after yesterday&#39;s gap higher https://seekingalpha.com/news/3236499-csx-downgraded-deutsche-bank-after-yesterdays-gap-higher?source=tweet\" data-url=\"https://seekingalpha.com/news/3236499-csx-downgraded-deutsche-bank-after-yesterdays-gap-higher\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3236493\" data-ts=\"1484945576\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INFI\" target=\"_blank\">INFI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3236493-infinity-pharmas-lead-product-candidate-ipiminus-549-shows-encouraging-results-in-preclinical\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Infinity Pharma&#39;s lead product candidate IPI-549 shows encouraging results in preclinical cancer testing; shares ahead 21%</a></h4><ul><li>Infinity Pharmaceuticals (<a href='https://seekingalpha.com/symbol/INFI' title='Infinity Pharmaceuticals, Inc.'>INFI</a> <font color='green'>+21.3%</font>) is up on triple normal volume in response to its <a href=\"https://seekingalpha.com/pr/16719293-infinity-presents-preclinical-data-phase-1-clinical-data-ipiminus-549-pi3k-keystone-symposia\" target=\"_blank\">announcement </a>of positive preclinical data for lead oncology candidate IPI-549. The results were presented at the Keystone Symposia Conference \"<a href=\"http://www.keystonesymposia.org/index.cfm?e=web.Meeting.Program&amp;meetingid=1437\" target=\"_blank\">PI3K Pathways in Immunology, Growth Disorders and Cancer</a>\" in Sante Fe, New Mexico.</li><li>Results from nine patients with advanced solid tumors showed that IPI-549 was able to overcome checkpoint inhibition by remodeling the immune-suppressive tumor microenvironment, principally by its effect on myeloid cells.</li><li>IPI-549 in currently being evaluated in a Phase 1 study as monotherapy and in combination with Bristol-Myers Squibb's (<a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a> <font color='red'>-11.1%</font>) Opdivo (nivolumab) in patients with advanced solid tumors, including non-small cell lung cancer, melanoma and squamous cell carcinoma of the head and neck whose tumors are treatment resistant.</li><li><a href=\"http://www.infi.com/home/research-development/pi3k/\" target=\"_blank\">IPI-549</a> is an orally available inhibitor of an enzyme called phosphoinositide-3-kinase (PI3K)-gamma that plays a key role in inflammation, immunity and cancer.</li></ul><div class=\"tiny-share-widget\" data-id=\"3236493\" data-linked=\"Infinity Pharma&#39;s lead product candidate IPI-549 shows encouraging results in preclinical cancer testing; shares ahead 21%\" data-tweet=\"$INFI $INFI $BMY - Infinity Pharma&#39;s lead product candidate IPI-549 shows encouraging results in preclinical cancer testing; shares ahead 21% https://seekingalpha.com/news/3236493-infinity-pharmas-lead-product-candidate-ipiminus-549-shows-encouraging-results-in-preclinical?source=tweet\" data-url=\"https://seekingalpha.com/news/3236493-infinity-pharmas-lead-product-candidate-ipiminus-549-shows-encouraging-results-in-preclinical\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:52 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3236494\" data-ts=\"1484945282\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/COL\" target=\"_blank\">COL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3236494-rockwell-collins-sees-new-jetliner-deliveries-rising-through-end-of-decade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rockwell Collins sees new jetliner deliveries rising through end of decade</a></h4><ul><li>Rockwell Collins (<a href='https://seekingalpha.com/symbol/COL' title='Rockwell Collins, Inc.'>COL</a> <font color='green'>+2.2%</font>) rises following better than expected <a href=\"https://seekingalpha.com/news/3236318-rockwell-collins-beats-0_06-misses-revenue\" target=\"_blank\">FQ1 earnings</a>, and the company <a href=\"http://www.marketwatch.com/story/rockwell-collins-confident-on-jetliner-deliveries-2017-01-20\" target=\"_blank\">expects new jetliner deliveries continuing to rise</a> through the end of the decade even with the slip in orders.</li><li>\"We're going to continue to see the narrow-body because of the strong  backlog, continue to ramp up at both [companies],\" CEO&nbsp;Kelly Ortberg said in today's <a href=\"https://seekingalpha.com/article/4038248-rockwell-collins-inc-2017-q1-results-earnings-call-slides\" target=\"_blank\">earnings conference call</a>, forecasting  that the order cycle would continue through 2020 when Boeing's new 777X  jet is due to enter service.</li><li>Ortberg expects a repeat of the previous cycle for big jets  when backlogs at Boeing and Airbus sustained production  even as orders dipped and more airlines sought to defer new aircraft.</li><li>The CEO also expresses optimism that the new Trump administration could spark a recovery in the business jet market after  years of flat or declining sales.</li><li>Ortberg expects the B/E Aerospace (BEAV <font color='red'>-0.1%</font>) acquisition to close this spring.</li></ul><div class=\"tiny-share-widget\" data-id=\"3236494\" data-linked=\"Rockwell Collins sees new jetliner deliveries rising through end of decade\" data-tweet=\"$COL - Rockwell Collins sees new jetliner deliveries rising through end of decade https://seekingalpha.com/news/3236494-rockwell-collins-sees-new-jetliner-deliveries-rising-through-end-of-decade?source=tweet\" data-url=\"https://seekingalpha.com/news/3236494-rockwell-collins-sees-new-jetliner-deliveries-rising-through-end-of-decade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:48 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3236490\" data-ts=\"1484944035\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CF\" target=\"_blank\">CF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3236490-cf-industries-upgraded-two-notches-to-buy-bofa\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CF Industries upgraded two notches to Buy at BofA</a></h4><ul>     <li>CF Industries (<a href='https://seekingalpha.com/symbol/CF' title='CF Industries Holdings, Inc.'>CF</a> <font color='green'>+5.5%</font>) shoots higher after BofA&nbsp;Merrill Lynch <a href=\"http://www.streetinsider.com/Analyst+Comments/BofAMerrill+Lynch+Upgrades+CF+Industries+%28CF%29+to+Buy%2C+Says+%22Consensus+Estimates+Now+Beatable%22/12442819.html\" target=\"_blank\">upgrades shares two notches to Buy</a> from Underperform with a $40 price target, lifted from $21.</li><li>BofA&nbsp;believes capacity rationalization is underway and that the nitrogen debate has shifted from the timing of the trough to the magnitude of the recovery.</li><li>UBS cut CF to Neutral from Buy <a href=\"https://seekingalpha.com/news/3234405-cf-industries-cut-neutral-ubs-valuation\" target=\"_blank\">last week</a>, primarily on  valuation following a run-up in the stock.</li></ul><div class=\"tiny-share-widget\" data-id=\"3236490\" data-linked=\"CF Industries upgraded two notches to Buy at BofA\" data-tweet=\"$CF - CF Industries upgraded two notches to Buy at BofA https://seekingalpha.com/news/3236490-cf-industries-upgraded-two-notches-to-buy-bofa?source=tweet\" data-url=\"https://seekingalpha.com/news/3236490-cf-industries-upgraded-two-notches-to-buy-bofa\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:27 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3236481\" data-ts=\"1484942401\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3236481-technology-top-gainers-losers-of-3-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 3:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/PRKR' title='ParkerVision, Inc.'>OTC:PRKR</a> <font color='green'>+36%</font>. <a href='https://seekingalpha.com/symbol/CPSH' title='CPS Technologies Corp.'>CPSH</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/TCX' title='Tucows Inc'>TCX</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/NAME' title='Rightside Group, Ltd.'>NAME</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/SWKS' title='Skyworks Solutions, Inc.'>SWKS</a> <font color='green'>+13%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/CRDS' title='Crossroads Systems, Inc.'>CRDS</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/VJET' title='voxeljet AG'>VJET</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/DYSL' title='Dynasil Corporation of America'>DYSL</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/MIME' title='Mimecast'>MIME</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/APDN' title='Applied DNA Sciences, Inc.'>APDN</a> <font color='red'>-4%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3236481\" data-linked=\"Technology - Top Gainers / Losers as of 3:00 pm\" data-tweet=\"$PRKR $CPSH $TCX - Technology - Top Gainers / Losers as of 3:00 pm https://seekingalpha.com/news/3236481-technology-top-gainers-losers-of-3-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3236481-technology-top-gainers-losers-of-3-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3236480\" data-ts=\"1484941264\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RAD\" target=\"_blank\">RAD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3236480-drugstore-investors-scramble-after-ftc-wildcard-pops-up\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Drugstore investors scramble after FTC wildcard pops up</a></h4><ul><li>Rite Aid (<a href='https://seekingalpha.com/symbol/RAD' title='Rite Aid Corporation'>RAD</a> <font color='red'>-11%</font>) and Fred's (<a href='https://seekingalpha.com/symbol/FRED' title='Fred&#39;s, Inc.'>FRED</a> <font color='red'>-3.3%</font>) have recovered from their lowest levels of the day after Bloomberg <a href=\"https://www.bloomberg.com/news/articles/2017-01-20/walgreens-said-to-face-u-s-antitrust-concerns-over-rite-aid-fix\" target=\"_blank\">reported</a> that the FTC isn't quite pleased with the proposed terms of the Walgreens (<a href='https://seekingalpha.com/symbol/WBA' title='Walgreens Boots Alliance, Inc.'>WBA</a> <font color='red'>-2.8%</font>)-Rite Aid divestiture plan.</li><li>Analysts think the deal for Fred's to acquire 865 Rite Aid may still go through, reminding that President Trump is poised to name three new members to the FTC commission.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3236435-rite-aid-freds-plummet-word-ftc-walgreens-deal-review\" target=\"_blank\">Rite Aid and Fred's plummet on word of FTC Walgreens deal review</a> (Jan. 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3236480\" data-linked=\"Drugstore investors scramble after FTC wildcard pops up\" data-tweet=\"$RAD $RAD $FRED - Drugstore investors scramble after FTC wildcard pops up https://seekingalpha.com/news/3236480-drugstore-investors-scramble-after-ftc-wildcard-pops-up?source=tweet\" data-url=\"https://seekingalpha.com/news/3236480-drugstore-investors-scramble-after-ftc-wildcard-pops-up\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>135&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3236478\" data-ts=\"1484941144\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SKYAY\" target=\"_blank\">SKYAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3236478-bt-group-hiking-broadband-fees-5minus-6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BT Group hiking broadband fees by 5-6%</a></h4><ul>   <li>BT Group (<a href='https://seekingalpha.com/symbol/BT' title='BT Group plc'>BT</a> <font color='green'>+2.3%</font>) is <a href=\"http://www.reuters.com/article/bt-prices-idUSL5N1FA3X9\" target=\"_blank\">raising prices</a> on a number of services in April, including hiking broadband fees by 5-6%, more than triple the rate of consumer inflation.</li>    <li>The company's charging an extra &pound;2/month (about $2.46) for its copper broadband customers, and those on faster Infinity lines may pay an extra &pound;2.50.</li>    <li>It's also charging more for calls and for some of its TV packages.</li>    <li>\"Customers will get a better package and improved service from us this year in exchange for paying a little more,\" says BT Consumer CEO John Petter; the company notes rivals Sky (<a href='https://seekingalpha.com/symbol/SKYAY' title='Sky Plc ADR'>OTCPK:SKYAY</a>), Virgin Media (NASDAQ:<a href='https://seekingalpha.com/symbol/LBTYA' title='Liberty Global, Inc.'>LBTYA</a>) and TalkTalk (<a href='https://seekingalpha.com/symbol/TKTCY' title='Talktalk Telecom Group, PLC ADR'>OTCPK:TKTCY</a>) raised prices or announced hikes in the past year.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3236478\" data-linked=\"BT Group hiking broadband fees by 5-6%\" data-tweet=\"$SKYAY $SKYAY $LBTYA - BT Group hiking broadband fees by 5-6% https://seekingalpha.com/news/3236478-bt-group-hiking-broadband-fees-5minus-6?source=tweet\" data-url=\"https://seekingalpha.com/news/3236478-bt-group-hiking-broadband-fees-5minus-6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:39 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3236477\" data-ts=\"1484939847\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SXCP\" target=\"_blank\">SXCP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3236477-suncokeminus-7-irs-excludes-cokemaking-qualifying-income-activity\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SunCoke -7% as IRS excludes cokemaking as qualifying income activity</a></h4><ul>     <li>SunCoke Energy Partners (<a href='https://seekingalpha.com/symbol/SXCP' title='SunCoke Energy Partners'>SXCP</a> <font color='red'>-6.7%</font>) says it is &ldquo;<a href=\"https://seekingalpha.com/pr/16718978-suncoke-energy-partners-l-p-issues-statement-mlp-qualifying-income-status\" target=\"_blank\">disappointed</a>\" in the decision by the IRS to exclude cokemaking as a qualifying income generating activity.</li><li>However, SXCP believes that income from its coke operations will be qualifying  income during the 10-year transition period contemplated by final  regulations.</li><li>Parent SunCoke Energy (<a href='https://seekingalpha.com/symbol/SXC' title='SunCoke Energy'>SXC</a> <font color='red'>-4.1%</font>) also is sharply lower.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3236477\" data-linked=\"SunCoke -7% as IRS excludes cokemaking as qualifying income activity\" data-tweet=\"$SXCP $SXCP $SXC - SunCoke -7% as IRS excludes cokemaking as qualifying income activity https://seekingalpha.com/news/3236477-suncokeminus-7-irs-excludes-cokemaking-qualifying-income-activity?source=tweet\" data-url=\"https://seekingalpha.com/news/3236477-suncokeminus-7-irs-excludes-cokemaking-qualifying-income-activity\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3236475\" data-ts=\"1484939128\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3236475-energy-materials-top-5-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top 5 Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> SGY <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/EMES' title='Emerge Energy Services LP'>EMES</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/WLKP' title='Westlake Chemical Partners LP'>WLKP</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/NAK' title='Northern Dynasty Minerals Ltd'>NAK</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/SAEX' title='SAExploration Holdings, Inc.'>SAEX</a> <font color='green'>+9%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/DELT' title='Delta Technology Holdings Limited'>DELT</a> <font color='red'>-14%</font>. URRE <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/SXCP' title='SunCoke Energy Partners'>SXCP</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/RKDA' title='Arcadia Biosciences'>RKDA</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/SJT' title='San Juan Basin Royalty Trust'>SJT</a> <font color='red'>-5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3236475\" data-linked=\"Energy/Materials - Top 5 Gainers / Losers as of 2:00 pm\" data-tweet=\"$TALO $EMES $WLKP - Energy/Materials - Top 5 Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3236475-energy-materials-top-5-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3236475-energy-materials-top-5-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:05 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3236461\" data-ts=\"1484935767\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SYF\" target=\"_blank\">SYF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3236461-synchrony-financialplus-1_6-after-earnings-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Synchrony Financial +1.6% after earnings beat</a></h4><ul><li>The beat shouldn't come as too much of a surprise, <a href=\"http://researchwiseny.btig.com/ResearchLibraryAnalec/DownloadResearch.aspx?E=gdbak-b\" target=\"_blank\">says BTIG's bullish Mark Palmer</a>, as it's the 10th consecutive quarter EPS has outpaced Street estimates.</li><li>Receivables growth of 12%, purchase volume growth of 9%, and net interest income growth of 13%.</li><li>The 2017 outlook calls for loan receivables growth of 7-9% this year - equal to what was guided for in 2016 (12% growth was actually posted).</li><li>Maybe somewhat worrying though is the expectation for the net charge-off rate to be 4.75-5% vs. 4.5% in 2016. Investors will remember the punishment inflicted on the share price last summer when management boosted its NCO expectation (that decline has been way more than erased since).</li><li>Palmer reiterates his Buy rating and $42 price target (17% upside).</li><li><a href='https://seekingalpha.com/symbol/SYF' title='Synchrony Financial'>SYF</a><font color='green'> +1.6%</font>&nbsp;to $36.17.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3236338-synchrony-financial-tops-estimates-credit-quality-slips\" target=\"_blank\">Synchrony Financial tops estimates as credit quality slips</a> (Jan. 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3236461\" data-linked=\"Synchrony Financial +1.6% after earnings beat\" data-tweet=\"$SYF - Synchrony Financial +1.6% after earnings beat https://seekingalpha.com/news/3236461-synchrony-financialplus-1_6-after-earnings-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3236461-synchrony-financialplus-1_6-after-earnings-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:09 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3236457\" data-ts=\"1484934365\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3236457-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> ETRM <font color='green'>+33%</font>. SGY <font color='green'>+32%</font>. <a href='https://seekingalpha.com/symbol/DFFN' title='Diffusion Pharmaceuticals Inc.'>DFFN</a> <font color='green'>+22%</font>. <a href='https://seekingalpha.com/symbol/GLBS' title='Globus Maritime Ltd.'>GLBS</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/TCX' title='Tucows Inc'>TCX</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/NAME' title='Rightside Group, Ltd.'>NAME</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/SWKS' title='Skyworks Solutions, Inc.'>SWKS</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/DGLY' title='Digital Ally, Inc.'>DGLY</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/HYGS' title='Hydrogenics Corporation'>HYGS</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/NM' title='Navios Maritime Holdings Inc.'>NM</a> <font color='green'>+11%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/PSTI' title='Pluristem Therapeutics, Inc.'>PSTI</a> <font color='red'>-23%</font>. <a href='https://seekingalpha.com/symbol/AFMD' title='Affimed Therapeutics'>AFMD</a> <font color='red'>-19%</font>. <a href='https://seekingalpha.com/symbol/DELT' title='Delta Technology Holdings Limited'>DELT</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/RAD' title='Rite Aid Corporation'>RAD</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/TDG' title='TransDigm Group Incorporated'>TDG</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a> <font color='red'>-11%</font>. MCUR <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/NFEC' title='NF Energy Saving Corp.'>NFEC</a> <font color='red'>-10%</font>. URRE <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/CRDS' title='Crossroads Systems, Inc.'>CRDS</a>&nbsp;<font color='red'>-8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3236457\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$RSLS $TALO $DFFN - Midday Gainers / Losers https://seekingalpha.com/news/3236457-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3236457-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3236455\" data-ts=\"1484934122\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UNH\" target=\"_blank\">UNH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3236455-health-insurers-may-benefit-from-repeal-of-aca-says-thestreets-gamm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Health insurers may benefit from repeal of ACA says TheStreet&#39;s Gamm</a></h4><ul><li>TheStreet's Scott Gamm <a href=\"https://www.thestreet.com/story/13960753/1/unitedhealth-aetna-and-humana-may-benefit-from-obamacare-repeal.html\" target=\"_blank\">reports </a>the potential appeal of the Affordable Care Act &#40;ACA&#41;, known as Obamacare, may be bullish for health insurers since the health exchange approach was unprofitable. Individuals buying coverage will be a lot more agreeable to their bottom lines, at least conceptually.</li><li>Jon Lieber, U.S. practice director at consultancy <a href=\"http://www.eurasiagroup.net/our-story\" target=\"_blank\">Eurasia Group</a> says without ACA's individual mandate and subsidies, though, few people will want to buy insurance. \"They're (the insurers) are going to struggle to provide insurance in the individual market if Obamacare is repealed,\" an ever-increasing likelihood considering the Republican majority in Congress.</li><li>If the insurers withdraw from the individual market and focus on employers, it would bode well financially since they have healthier pools of people.</li><li>Related tickers: (<a href='https://seekingalpha.com/symbol/UNH' title='UnitedHealth Group Inc.'>UNH</a> <font color='red'>-0.4%</font>)(<a href='https://seekingalpha.com/symbol/AET' title='Aetna, Inc.'>AET</a> <font color='red'>-0.3%</font>)(<a href='https://seekingalpha.com/symbol/CI' title='Cigna Corporation'>CI</a> <font color='green'>+0.2%</font>)(<a href='https://seekingalpha.com/symbol/HUM' title='Humana Inc.'>HUM</a> <font color='red'>-1.3%</font>)(<a href='https://seekingalpha.com/symbol/ANTM' title='Anthem, Inc.'>ANTM</a> <font color='green'>+1.1%</font>)(<a href='https://seekingalpha.com/symbol/MOH' title='Molina Healthcare, Inc.'>MOH</a> <font color='green'>+1.3%</font>)(<a href='https://seekingalpha.com/symbol/WCG' title='WellCare Health Plans, Inc.'>WCG</a> <font color='green'>+0.8%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3236455\" data-linked=\"Health insurers may benefit from repeal of ACA says TheStreet&#39;s Gamm\" data-tweet=\"$UNH $UNH $AET - Health insurers may benefit from repeal of ACA says TheStreet&#39;s Gamm https://seekingalpha.com/news/3236455-health-insurers-may-benefit-from-repeal-of-aca-says-thestreets-gamm?source=tweet\" data-url=\"https://seekingalpha.com/news/3236455-health-insurers-may-benefit-from-repeal-of-aca-says-thestreets-gamm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3236456\" data-ts=\"1484934086\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AZZ\" target=\"_blank\">AZZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3236456-azz-westinghouse-reveal-new-agreement-end-prior-nuclear-logistics-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AZZ, Westinghouse reveal new agreement, end prior nuclear logistics deal</a></h4><ul>     <li>AZZ Inc. (<a href='https://seekingalpha.com/symbol/AZZ' title='AZZ incorporated'>AZZ</a> <font color='green'>+2.2%</font>) announces a <a href=\"https://seekingalpha.com/pr/16718976-azz-inc-westinghouse-electric-company-announce-teaming-agreement-mutually-agree-terminate\" target=\"_blank\">teaming agreement</a> with Westinghouse Electric to jointly market their safety-related equipment solutions to the nuclear industry, and agree to terminate their prior nuclear logistics transaction.</li>     <li>AZZ&nbsp;CEO&nbsp;Tom Ferguson says the companies \"made  significant progress but it became apparent  that the market needed us to focus on building our heritage businesses.\"</li>     <li>AZZ says its Nuclear Logistics LLC subsidiary is the largest third-party supplier of safety related equipment to the nuclear industry.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3236456\" data-linked=\"AZZ, Westinghouse reveal new agreement, end prior nuclear logistics deal\" data-tweet=\"$AZZ - AZZ, Westinghouse reveal new agreement, end prior nuclear logistics deal https://seekingalpha.com/news/3236456-azz-westinghouse-reveal-new-agreement-end-prior-nuclear-logistics-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3236456-azz-westinghouse-reveal-new-agreement-end-prior-nuclear-logistics-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3236451\" data-ts=\"1484932277\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IDXG\" target=\"_blank\">IDXG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3236451-interpace-inks-direct-placement-of-stock-and-warrants-4_69\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Interpace inks direct placement of stock and warrants at $4.69</a></h4><ul><li>Interpace Diagnostics (<a href='https://seekingalpha.com/symbol/IDXG' title='Interpace Diagnostics Group, Inc.'>IDXG</a> <font color='green'>+5.9%</font>) enters into a <a href=\"https://www.sec.gov/Archives/edgar/data/1054102/000143774917000903/ex99-1.htm\" target=\"_blank\">securities purchase agreement</a> with three institutional investors for the direct sale of 855K shares of common stock at $4.69. Each share bought will have an accompanying five-year immediately exercisable warrant to purchase one share of common at $4.69.</li><li>Gross proceeds will be $4M. Closing date is January 25.</li><li>Net proceeds will fund working capital, the repayment of indebtedness and general corporate purposes.</li><li>Yesterday's close was $4.60.</li></ul><div class=\"tiny-share-widget\" data-id=\"3236451\" data-linked=\"Interpace inks direct placement of stock and warrants at $4.69\" data-tweet=\"$IDXG - Interpace inks direct placement of stock and warrants at $4.69 https://seekingalpha.com/news/3236451-interpace-inks-direct-placement-of-stock-and-warrants-4_69?source=tweet\" data-url=\"https://seekingalpha.com/news/3236451-interpace-inks-direct-placement-of-stock-and-warrants-4_69\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:11 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3236449\" data-ts=\"1484931679\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AFMD\" target=\"_blank\">AFMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3236449-affimed-prices-equity-offering-shares-ease-21\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Affimed prices equity offering; shares ease 21%</a></h4><ul><li>Affimed N.V. (<a href='https://seekingalpha.com/symbol/AFMD' title='Affimed Therapeutics'>AFMD</a> <font color='red'>-20.9%</font>) slumps on a 10x surge in volume in response to the <a href=\"https://seekingalpha.com/pr/16719159-affimed-announces-pricing-public-offering-common-stock\" target=\"_blank\">pricing </a>of its public offering of 10M shares of common stock at $1.80. Underwriters over-allotment is an additional 1.5M shares. Net proceeds should be ~$16.9M. Closing date is January 25.</li><li>Yesterday's close was $2.15.</li></ul><div class=\"tiny-share-widget\" data-id=\"3236449\" data-linked=\"Affimed prices equity offering; shares ease 21%\" data-tweet=\"$AFMD - Affimed prices equity offering; shares ease 21% https://seekingalpha.com/news/3236449-affimed-prices-equity-offering-shares-ease-21?source=tweet\" data-url=\"https://seekingalpha.com/news/3236449-affimed-prices-equity-offering-shares-ease-21\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3236448\" data-ts=\"1484931654\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3236448-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/PME' title='Pingtan Marine Enterprise Ltd.'>PME</a> <font color='green'>+11%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/DFBG-OLD' title='Differential Brands Group Inc.'>DFBG-OLD</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3236448\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$PME $DFBG-OLD - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3236448-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3236448-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3236445\" data-ts=\"1484931301\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NE\" target=\"_blank\">NE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3236445-noble-corpplus-9-after-winning-contract-extension-for-pair-of-rigs\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Noble Corp. +9% after winning contract extension for pair of rigs</a></h4><ul>     <li>Noble Corp. (<a href='https://seekingalpha.com/symbol/NE' title='Noble Corporation plc'>NE</a> <font color='green'>+9.2%</font>) shoots higher after <a href=\"http://www.offshoreenergytoday.com/noble-scoops-more-jack-up-work-with-saudi-aramco/\" target=\"_blank\">securing contract extensions</a> for a pair of jackup rigs from Saudi Aramco.</li>     <li>NE's <a href=\"http://phx.corporate-ir.net/phoenix.zhtml?c=98046&amp;p=irol-reportsOther\" target=\"_blank\">latest fleet status report</a> shows the <em>Noble Scott Marks</em> jack-up rig received a five-year contract extension with Aramco, with a slight dayrate reduction to $159K from $167K previously.</li>     <li>Also, the <em>Noble Roger Lewis</em> jack-up rig was awarded a five-year contract extension from Aramco, also at a reduced dayrate of $159K from&nbsp;$167K.</li>     <li>BofA&nbsp;Merrill <a href=\"http://www.streetinsider.com/Upgrades/BofAMerrill+Lynch+Upgrades+Noble+Corporation+%28NE%29+to+Neutral/12442741.html\" target=\"_blank\">upgrades</a> shares to Neutral from Underperform, saying the contract extensions were expected but that the strong rate is a positive sign for the overall jackup market.</li></ul><div class=\"tiny-share-widget\" data-id=\"3236445\" data-linked=\"Noble Corp. +9% after winning contract extension for pair of rigs\" data-tweet=\"$NE - Noble Corp. +9% after winning contract extension for pair of rigs https://seekingalpha.com/news/3236445-noble-corpplus-9-after-winning-contract-extension-for-pair-of-rigs?source=tweet\" data-url=\"https://seekingalpha.com/news/3236445-noble-corpplus-9-after-winning-contract-extension-for-pair-of-rigs\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3236437\" data-ts=\"1484929336\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DFFN\" target=\"_blank\">DFFN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3236437-diffusion-pharma-another-bio-nano-cap-on-move-shares-up-2_5-fold-in-two-weeks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Diffusion Pharma another bio nano cap on the move; shares up 2.5-fold in two weeks</a></h4><ul><li>The remarkable up moves in tiny biotechs this month includes nano cap Diffusion Pharmaceuticals (<a href='https://seekingalpha.com/symbol/DFFN' title='Diffusion Pharmaceuticals Inc.'>DFFN</a> <font color='green'>+18.2%</font>). Shares almost tripled on January 10 before retracing 73%. With today's move, prices are still ahead 154% since January 9.</li><li>No particular news accounts for the action. The clinical-stage firm develops treatments designed to improve the efficacy of radiotherapy and chemotherapy in cancer patients. Its lead product candidate is <a href=\"http://www.diffusionpharma.com/product-pipeline/overview-trans-sodium-crocetinate-tsc/\" target=\"_blank\">Trans Sodium Crocetinate</a> &#40;TSC&#41; which <a href=\"http://www.diffusionpharma.com/technology/technology-overview/\" target=\"_blank\">promotes the diffusion of oxygen</a> through blood plasma and into the hypoxic (oxygen deprived) tumor microenvironment. Cancer cells thrive in hypoxic environments which involve changes that make the tumors resistant to treatment. TSC is in Phase 2 development in glioblastoma, the most common type of brain tumor.</li></ul><div class=\"tiny-share-widget\" data-id=\"3236437\" data-linked=\"Diffusion Pharma another bio nano cap on the move; shares up 2.5-fold in two weeks\" data-tweet=\"$DFFN - Diffusion Pharma another bio nano cap on the move; shares up 2.5-fold in two weeks https://seekingalpha.com/news/3236437-diffusion-pharma-another-bio-nano-cap-on-move-shares-up-2_5-fold-in-two-weeks?source=tweet\" data-url=\"https://seekingalpha.com/news/3236437-diffusion-pharma-another-bio-nano-cap-on-move-shares-up-2_5-fold-in-two-weeks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:22 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3236439\" data-ts=\"1484928932\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FENG\" target=\"_blank\">FENG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3236439-phoenix-new-media-extends-loans-to-yidian\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Phoenix New Media extends loans to Yidian</a></h4><ul>   <li>Phoenix New Media (<a href='https://seekingalpha.com/symbol/FENG' title='Phoenix New Media Limited'>FENG</a> <font color='green'>+4.4%</font>) has <a href=\"https://seekingalpha.com/pr/16718972-phoenix-new-media-announces-extension-loans-yidian\" target=\"_blank\">extended a pair of loans</a> granted to its unit Particle Inc., the owners of lifestyle app Yidian Zixun.</li>    <li>One loan for $14.8M will mature in August after being extended. The other, about $6.8M, was granted in November and will mature in November 2017 after extension.</li>    <li>In connection with the extension, Particle also granted Phoenix the right to convert all or part of the August loan into Series D1 preferred shares.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3236439\" data-linked=\"Phoenix New Media extends loans to Yidian\" data-tweet=\"$FENG - Phoenix New Media extends loans to Yidian https://seekingalpha.com/news/3236439-phoenix-new-media-extends-loans-to-yidian?source=tweet\" data-url=\"https://seekingalpha.com/news/3236439-phoenix-new-media-extends-loans-to-yidian\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:15 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3236438\" data-ts=\"1484928838\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CHK\" target=\"_blank\">CHK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3236438-chesapeake-energy-is-still-buy-suntrust-says\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Chesapeake Energy is still a Buy, SunTrust says</a></h4><ul><li>Chesapeake Energy (<a href='https://seekingalpha.com/symbol/CHK' title='Chesapeake Energy Corporation'>CHK</a> <font color='green'>+3.4%</font>) punches higher following this morning's news that it was <a href=\"https://seekingalpha.com/news/3236336-chesapeake-issues-18_8m-shares-buy-preferred-shares\" target=\"_blank\">exchanging</a> common stock for preferred shares.</li><li>Although the move may rankle some investors, SunTrust analysts <a href=\"http://blogs.barrons.com/stockstowatchtoday/2017/01/20/chesapeake-energy-why-one-analyst-says-its-still-a-buy/\" target=\"_blank\">reiterate their Buy rating</a>, keeping the faith after some analysts a year ago were actively wondering if CHK would have to file for bankruptcy.</li><li>SunTrust sees CHK enjoying a number of catalysts in the coming months, as the company plans to release numerous well results with improved operating efficiencies from newer plays, such as the Power River Basin or STACK, as well as continued plays, such as the Haynesville, Eagle Ford or Utica.</li><li>The firm notes that strong operations highlighted at the recent analyst day with $5-$10/bbl replacement costs should help CHK generate positive free cash flow next year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3236438\" data-linked=\"Chesapeake Energy is still a Buy, SunTrust says\" data-tweet=\"$CHK - Chesapeake Energy is still a Buy, SunTrust says https://seekingalpha.com/news/3236438-chesapeake-energy-is-still-buy-suntrust-says?source=tweet\" data-url=\"https://seekingalpha.com/news/3236438-chesapeake-energy-is-still-buy-suntrust-says\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>36&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3236435\" data-ts=\"1484928380\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RAD\" target=\"_blank\">RAD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3236435-rite-aid-and-freds-plummet-on-word-of-ftc-walgreens-deal-review\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rite Aid and Fred&#39;s plummet on word of FTC Walgreens deal review</a></h4><ul><li>Rite Aid (<a href='https://seekingalpha.com/symbol/RAD' title='Rite Aid Corporation'>RAD</a> <font color='red'>-11.5%</font>) and Fred's (<a href='https://seekingalpha.com/symbol/FRED' title='Fred&#39;s, Inc.'>FRED</a> <font color='red'>-7.1%</font>) dive on indications that the FTC isn't satisfied with the planned merger between Walgreens Boots Alliance (<a href='https://seekingalpha.com/symbol/WBA' title='Walgreens Boots Alliance, Inc.'>WBA</a> <font color='red'>-2.1%</font>) and Rite Aid.</li><li>Share of Rite Aid and Fred's have been halted.</li><li>The story is still developing.</li></ul><div class=\"tiny-share-widget\" data-id=\"3236435\" data-linked=\"Rite Aid and Fred&#39;s plummet on word of FTC Walgreens deal review\" data-tweet=\"$RAD $RAD $FRED - Rite Aid and Fred&#39;s plummet on word of FTC Walgreens deal review https://seekingalpha.com/news/3236435-rite-aid-and-freds-plummet-on-word-of-ftc-walgreens-deal-review?source=tweet\" data-url=\"https://seekingalpha.com/news/3236435-rite-aid-and-freds-plummet-on-word-of-ftc-walgreens-deal-review\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>128&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3236417\" data-ts=\"1484928136\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3236417-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> ETRM <font color='green'>+43%</font>. <a href='https://seekingalpha.com/symbol/DFFN' title='Diffusion Pharmaceuticals Inc.'>DFFN</a> <font color='green'>+22%</font>. <a href='https://seekingalpha.com/symbol/ARLZ-OLD' title='Aralez Pharmaceuticals Inc.'>ARLZ-OLD</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/GNVC' title='GenVec, Inc.'>GNVC</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/MDVX' title='Medovex Inc.'>OTC:MDVX</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/PSTI' title='Pluristem Therapeutics, Inc.'>PSTI</a> <font color='red'>-23%</font>. <a href='https://seekingalpha.com/symbol/AFMD' title='Affimed Therapeutics'>AFMD</a> <font color='red'>-21%</font>. MCUR <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/SGYP' title='Synergy Pharmaceuticals, Inc.'>SGYP</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a> <font color='red'>-9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3236417\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$RSLS $DFFN $ARLZ-OLD - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3236417-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3236417-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3236430\" data-ts=\"1484927312\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KSU\" target=\"_blank\">KSU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3236430-weak-peso-whacks-results-kansas-city-southern\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Weak peso whacks results at Kansas City Southern</a></h4><ul> <li>Kansas City Southern (<a href='https://seekingalpha.com/symbol/KSU' title='Kansas City Southern'>KSU</a> <font color='green'>+2.2%</font>) reports Q4 net income of $120M vs. $133M a year ago as weakness with the Mexican peso factored in.</li> <li>Earnings were 3% lower in the quarter due to the peso slide.</li> <li>During the earnings conference call, CEO Patrick Ottensmeyer said the company still has many question about U.S.-Mexico relations as the new administration takes over.</li> <li>Looking ahead, Kansas City Southern sees capex spending of $550M to $560M this year.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3236357-kansas-city-southern-beats-0_04-misses-revenue\" target=\"_blank\">Kansas City Southern beats by $0.04, misses on revenue</a> (Jan. 20)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3236430\" data-linked=\"Weak peso whacks results at Kansas City Southern\" data-tweet=\"$KSU - Weak peso whacks results at Kansas City Southern https://seekingalpha.com/news/3236430-weak-peso-whacks-results-kansas-city-southern?source=tweet\" data-url=\"https://seekingalpha.com/news/3236430-weak-peso-whacks-results-kansas-city-southern\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:48 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3236429\" data-ts=\"1484927175\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/I\" target=\"_blank\">I</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3236429-intelsat-closes-on-debt-exchange-offer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intelsat closes on debt exchange offer</a></h4><ul>   <li>Intelsat (<a href='https://seekingalpha.com/symbol/I' title='Intelsat SA'>I</a> <font color='green'>+3.9%</font>) has wrapped its <a href=\"https://seekingalpha.com/pr/16718957-intelsat-announces-final-results-exchange-offer-intelsat-luxembourg-s-certain-notes\" target=\"_blank\">private exchange offer</a> for notes at Intelsat Luxembourg, with $403.3M in 2018 notes tendered and accepted by the early deadline.</li>    <li>Intelsat Luxembourg had offered to exchange 6.75% senior notes due 2018 for newly issued 12.5% senior notes due 2024.</li>    <li>The company will cancel all the 2018 notes it acquires in the offer.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3236429\" data-linked=\"Intelsat closes on debt exchange offer\" data-tweet=\"$I - Intelsat closes on debt exchange offer https://seekingalpha.com/news/3236429-intelsat-closes-on-debt-exchange-offer?source=tweet\" data-url=\"https://seekingalpha.com/news/3236429-intelsat-closes-on-debt-exchange-offer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3236428\" data-ts=\"1484926890\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TDG\" target=\"_blank\">TDG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3236428-transdigm-valeant-of-aerospace-industry-citron-report-says\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TransDigm &quot;the Valeant of the aerospace industry,&quot; Citron report says</a></h4><ul>     <li>Transdigm (<a href='https://seekingalpha.com/symbol/TDG' title='TransDigm Group Incorporated'>TDG</a> <font color='red'>-9.6%</font>) shares are falling sharply following a <a href=\"http://www.citronresearch.com/wp-content/uploads/2017/01/TDG-final-a.pdf\" target=\"_blank\">negative report</a> from Citron Research that calls the company \"the Valeant of the aerospace industry.\"</li>     <li>While Boeing and Lockheed have gained the most notice from Pres.-elect Trump for high prices, \"everyone in the aerospace industry knows that [Transdigm] stands out when it comes to egregious price increases foisted on the government,\" Citron says.</li>     <li>The \"ugly underbelly\" of TDG's business is that aggressive Y/Y price increases are the only thing shielding the company from revealing negative organic growth of close to -10%, according to the report.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3236428\" data-linked=\"TransDigm &quot;the Valeant of the aerospace industry,&quot; Citron report says\" data-tweet=\"$TDG - TransDigm &quot;the Valeant of the aerospace industry,&quot; Citron report says https://seekingalpha.com/news/3236428-transdigm-valeant-of-aerospace-industry-citron-report-says?source=tweet\" data-url=\"https://seekingalpha.com/news/3236428-transdigm-valeant-of-aerospace-industry-citron-report-says\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3236426\" data-ts=\"1484926785\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RSLS\" target=\"_blank\">RSLS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3236426-enteromedics-tries-to-regain-momentum-shares-up-51\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EnteroMedics tries to regain momentum; shares up 51%</a></h4><ul><li>The white knuckle ride with EnteroMedics (ETRM <font color='green'>+51.3%</font>) continues in early trading on triple normal volume. Shares rocketed almost 15-fold in five days recently after the company reported that two new medical centers had incorporated its vBloc obesity treatment into their practices. The gain was short-lived however. Shares retraced 80% before recovering.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3233660-enteromedics-says-two-institutions-line-vbloc-shares-126-percent\" target=\"_blank\">EnteroMedics says two more institutions on line with vBloc; shares up 126%</a> (Jan. 5)</li></ul><div class=\"tiny-share-widget\" data-id=\"3236426\" data-linked=\"EnteroMedics tries to regain momentum; shares up 51%\" data-tweet=\"$RSLS - EnteroMedics tries to regain momentum; shares up 51% https://seekingalpha.com/news/3236426-enteromedics-tries-to-regain-momentum-shares-up-51?source=tweet\" data-url=\"https://seekingalpha.com/news/3236426-enteromedics-tries-to-regain-momentum-shares-up-51\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:39 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3236423\" data-ts=\"1484926183\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SGYP\" target=\"_blank\">SGYP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3236423-synergy-pharma-down-8-on-increased-volume-on-possible-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Synergy Pharma down 8% on increased volume on possible equity offering</a></h4><ul><li>The exciting ride for stockholders of Synergy Pharmaceuticals (<a href='https://seekingalpha.com/symbol/SGYP' title='Synergy Pharmaceuticals, Inc.'>SGYP</a> <font color='red'>-7.5%</font>) continues. Shares are down on more than a 30% spike in volume and are down almost 15% since January 5 despite the recent FDA approval of Trulance.</li><li>This type of behavior regularly portends an equity offering.</li></ul><div class=\"tiny-share-widget\" data-id=\"3236423\" data-linked=\"Synergy Pharma down 8% on increased volume on possible equity offering\" data-tweet=\"$SGYP $SGYP-OLD - Synergy Pharma down 8% on increased volume on possible equity offering https://seekingalpha.com/news/3236423-synergy-pharma-down-8-on-increased-volume-on-possible-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3236423-synergy-pharma-down-8-on-increased-volume-on-possible-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>56&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3236422\" data-ts=\"1484925896\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EFX\" target=\"_blank\">EFX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3236422-equifax-down-1_9-after-goldman-cuts-to-sell\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Equifax down 1.9% after Goldman cuts to Sell</a></h4><ul><li>via Bloomberg</li><li>Out of 16 sell-side shops covering Equifax (<a href='https://seekingalpha.com/symbol/EFX' title='Equifax Inc.'>EFX</a> <font color='red'>-1.9%</font>), Goldman becomes the only one rating the shares a Sell after analyst Andrew Benjamin's downgrade.</li><li>He takes note of the stock's premium valuation even as he expects revenue growth to slow to 7% this year from 12% in 2016.</li><li>The macro backdrop for both Equifax and peer Transunion (NYSE:<a href='https://seekingalpha.com/symbol/TRU' title='TransUnion'>TRU</a>) - which Benjamin rates a Neutral - should worsen over the next two years, says Benjamin.</li><li>His price target on EFX of $100 is&nbsp;<font color='red'>nearly 20% less</font>&nbsp;than yesterday's close.</li></ul><div class=\"tiny-share-widget\" data-id=\"3236422\" data-linked=\"Equifax down 1.9% after Goldman cuts to Sell\" data-tweet=\"$EFX $EFX $TRU - Equifax down 1.9% after Goldman cuts to Sell https://seekingalpha.com/news/3236422-equifax-down-1_9-after-goldman-cuts-to-sell?source=tweet\" data-url=\"https://seekingalpha.com/news/3236422-equifax-down-1_9-after-goldman-cuts-to-sell\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3236419\" data-ts=\"1484925557\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IDXG\" target=\"_blank\">IDXG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3236419-interpace-inks-deal-treatment-advisor-to-provide-tests-shares-up-30\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Interpace inks deal with treatment advisor to provide tests; shares up 30%</a></h4><ul><li>Interpace Diagnostics (<a href='https://seekingalpha.com/symbol/IDXG' title='Interpace Diagnostics Group, Inc.'>IDXG</a> <font color='green'>+30.4%</font>) jumps out of gate on more than double normal volume in response to its <a href=\"https://seekingalpha.com/pr/16719025-interpace-diagnostics-announces-new-partnership-israeli-specialty-services-provider\" target=\"_blank\">announcement </a>of an agreement with Tel Aviv-based Best Med Opinion Ltd, a provider of second opinion and clinical services for doctors and patients in Israel and certain other countries.</li><li>Best Med will provide its clients with information regarding the company's ThyGenX, ThyraMir and PancraGen tests and will manage the sample collecting and shipping logistics when the tests are selected to assist in treatment decisions. Best Med will be the exclusive provider of Interpace's products in Israel.</li><li>Financial terms are not disclosed.</li></ul><div class=\"tiny-share-widget\" data-id=\"3236419\" data-linked=\"Interpace inks deal with treatment advisor to provide tests; shares up 30%\" data-tweet=\"$IDXG - Interpace inks deal with treatment advisor to provide tests; shares up 30% https://seekingalpha.com/news/3236419-interpace-inks-deal-treatment-advisor-to-provide-tests-shares-up-30?source=tweet\" data-url=\"https://seekingalpha.com/news/3236419-interpace-inks-deal-treatment-advisor-to-provide-tests-shares-up-30\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:19 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3236411\" data-ts=\"1484924561\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IAC\" target=\"_blank\">IAC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3236411-guggenheim-securities-downgrades-iac-match-group\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Guggenheim Securities downgrades IAC, Match Group</a></h4><ul><li>Lowering both (<a href=\"http://www.streetinsider.com/Downgrades/Guggenheim+Downgrades+IACInterActiveCorp+%28IAC%29+to+Neutral/12442811.html\" target=\"_blank\">IAC</a>, <a href=\"http://www.streetinsider.com/Downgrades/Guggenheim+Downgrades+Match+Group+%28MTCH%29+to+Neutral/12442812.html\" target=\"_blank\">Match Group</a>) from Buy to Neutral.</li><li>IAC (NASDAQ:<a href='https://seekingalpha.com/symbol/IAC' title='IAC/InterActiveCorp'>IAC</a>)&nbsp;<font color='red'>-1.69%</font>,&nbsp;Match Group (NASDAQ:<a href='https://seekingalpha.com/symbol/MTCH' title='Match Group, Inc.'>MTCH</a>)&nbsp;<font color='red'>-1.46%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3236411\" data-linked=\"Guggenheim Securities downgrades IAC, Match Group\" data-tweet=\"$IAC $IAC $MTCH - Guggenheim Securities downgrades IAC, Match Group https://seekingalpha.com/news/3236411-guggenheim-securities-downgrades-iac-match-group?source=tweet\" data-url=\"https://seekingalpha.com/news/3236411-guggenheim-securities-downgrades-iac-match-group\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3236408\" data-ts=\"1484924111\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PG\" target=\"_blank\">PG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3236408-procter-gamble-runs-to-post-election-high\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Procter &amp; Gamble runs to post-election high</a></h4><ul> <li>A boost by Procter &amp; Gamble (<a href='https://seekingalpha.com/symbol/PG' title='The Procter & Gamble Company'>PG</a> <font color='green'>+2.5%</font>) in its forecast for fiscal year organic sales growth to 2% to 3% is catching the attention of analysts.</li> <li>Jefferies likes the strength shown by P&amp;G in the health care and baby/feminine/family care segments, although it notes that harder comparisons are ahead for the company.</li> <li>Wells Fargo is calling attention to the flat pricing during the quarter and the implication that competition is holding back price hikes.</li><li>Source: Bloomberg</li> <li>Shares of Procter &amp; Gamble are at their highest level since the U.S. election.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3236327-procter-and-gamble-beats-0_02-beats-revenue\" target=\"_blank\">Procter &amp; Gamble beats by $0.02, beats on revenue</a> (Jan. 20)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3236335-procter-and-gamble-plus-2-percent-margins-impress\" target=\"_blank\">Procter &amp; Gamble +2% after margins impress</a> (Jan. 20)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3236408\" data-linked=\"Procter &amp; Gamble runs to post-election high\" data-tweet=\"$PG - Procter &amp; Gamble runs to post-election high https://seekingalpha.com/news/3236408-procter-gamble-runs-to-post-election-high?source=tweet\" data-url=\"https://seekingalpha.com/news/3236408-procter-gamble-runs-to-post-election-high\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3236405\" data-ts=\"1484924012\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GTN\" target=\"_blank\">GTN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3236405-gray-televisionplus-2_1-on-upbeat-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gray Television +2.1% on upbeat guidance</a></h4><ul>   <li>Gray Television (NYSE:<a href='https://seekingalpha.com/symbol/GTN' title='Gray Television, Inc.'>GTN</a>) is <font color='green'>up 2.1%</font> after <a href=\"https://seekingalpha.com/pr/16719137-gray-announces-proposed-refinancing-senior-credit-facility-updates-guidance-4th-quarter-2016\" target=\"_blank\">updating guidance</a> on its upcoming quarterly report, with revenues set to exceed its previous high-side estimate of $237M.</li>    <li>The company now expects to report revenue between $237M and $238M, which would represent a 40% Y/Y gain. Political advertising revenue should exceed previous guidance for $48M, coming in between $48.25M and $48.75M. Broadcast operating expense will come in higher than expected as well, between $128M and $129M.</li>    <li>The company expects to report about $325.2M in cash on hand, and $1.78B in total debt. Total leverage ratio should be between 5.5 and 5.7 times.</li>    <li>The company also said it is proposing to refinance its senior credit facility, possibly including extending revolving credit to February 2022 and boosting it to $100M from a current $60M, and extending a $556.4M term loan to February 2024 from June 2021.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3236405\" data-linked=\"Gray Television +2.1% on upbeat guidance\" data-tweet=\"$GTN - Gray Television +2.1% on upbeat guidance https://seekingalpha.com/news/3236405-gray-televisionplus-2_1-on-upbeat-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3236405-gray-televisionplus-2_1-on-upbeat-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:53 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3236392\" data-ts=\"1484921926\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DPZ\" target=\"_blank\">DPZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3236392-keybanc-positive-on-dominos-pizza\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">KeyBanc positive on Domino&#39;s Pizza</a></h4><ul> <li>KeyBanc Capital Markets upgrades Domino's Pizza (NYSE:<a href='https://seekingalpha.com/symbol/DPZ' title='Domino&#39;s Pizza, Inc.'>DPZ</a>) to Overweight from Sector Weight after factoring in the new retail climate (wages, corporate taxes, spending).</li> <li>While a positive outlook on Domino's is not uncommon on Wall Street (8 Buys, 9 Holds, No Sells), <a href=\"http://www.cnbc.com/2017/01/20/early-movers-ge-pg-ibm-axp-dpz-wfc-more.html\" target=\"_blank\">underpinning</a> KeyBanc's optimism on the restaurant stock is the strong digital platform and growth potential for the pizza chain.</li><li>KeyBanc assigns a price target of $200 to Domino's.</li> <li>DPZ <font color='green'>+0.88%</font> premarket to $167.50.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3236392\" data-linked=\"KeyBanc positive on Domino&#39;s Pizza\" data-tweet=\"$DPZ - KeyBanc positive on Domino&#39;s Pizza https://seekingalpha.com/news/3236392-keybanc-positive-on-dominos-pizza?source=tweet\" data-url=\"https://seekingalpha.com/news/3236392-keybanc-positive-on-dominos-pizza\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:18 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3236390\" data-ts=\"1484921831\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AXP\" target=\"_blank\">AXP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3236390-amexminus-2-premarket-sell-side-digests-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AmEx -2% premarket as sell-side digests Q4 results</a></h4><ul><li>The EPS miss is \"troubling\" says Nomura's Bill Carcache, with the bull case \"highly susceptible to unraveling.\" His worry is that AmEx (NYSE:<a href='https://seekingalpha.com/symbol/AXP' title='American Express Company'>AXP</a>) is in a secular decline, and now faces the same growth headwinds as peers as provisions grow faster than loans. He reiterates his Reduce rating and $63 price target (<font color='red'>18% downside</font>).</li><li>A bull on the stock, Compass Point's John Williams says investors are overlooking the significant competitive advantage of wealthy customers' spending power. Progress the company made on expense cuts should ease \"considerable skepticism\" about the company's ability on that front.</li><li>Neutral on the stock, Piper's Jason Deleeuw says he's starting to \"turn positive\" as easier comps are coming in H2, and consumer finance beginning today could be about to enter a more favorable regulatory/macro backdrop.</li><li>Shares&nbsp;<font color='red'>-2%</font>&nbsp;to $75.20 premarket</li><li>Previously: <a href=\"https://seekingalpha.com/news/3236223-amex-modestly-lower-bottom-line-miss\" target=\"_blank\">AmEx modestly lower after bottom line miss</a> (Jan. 19)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3236209-american-express-misses-0_07-beats-revenue\" target=\"_blank\">American Express misses by $0.07, beats on revenue</a> (Jan. 19)</li></ul><div class=\"tiny-share-widget\" data-id=\"3236390\" data-linked=\"AmEx -2% premarket as sell-side digests Q4 results\" data-tweet=\"$AXP - AmEx -2% premarket as sell-side digests Q4 results https://seekingalpha.com/news/3236390-amexminus-2-premarket-sell-side-digests-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3236390-amexminus-2-premarket-sell-side-digests-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:17 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3236389\" data-ts=\"1484921755\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3236389-premarket-gainers-losers-of-9-10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers / Losers as of 9:10 am</a></h4><ul> <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/IDXG' title='Interpace Diagnostics Group, Inc.'>IDXG</a> <font color='green'>+63%</font>. <a href='https://seekingalpha.com/symbol/GLBS' title='Globus Maritime Ltd.'>GLBS</a> <font color='green'>+40%</font>. <a href='https://seekingalpha.com/symbol/WLKP' title='Westlake Chemical Partners LP'>WLKP</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/ESEA' title='Euroseas Ltd.'>ESEA</a> <font color='green'>+5%</font>. ETRM <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/SWKS' title='Skyworks Solutions, Inc.'>SWKS</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/EMES' title='Emerge Energy Services LP'>EMES</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/AREX' title='Approach Resources Inc.'>AREX</a> <font color='green'>+5%</font>. <a href='https://seekingalpha.com/symbol/NE' title='Noble Corporation plc'>NE</a> <font color='green'>+5%</font>.</li> <li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/PSTI' title='Pluristem Therapeutics, Inc.'>PSTI</a> <font color='red'>-22%</font>. <a href='https://seekingalpha.com/symbol/AFMD' title='Affimed Therapeutics'>AFMD</a> <font color='red'>-19%</font>. <a href='https://seekingalpha.com/symbol/DELT' title='Delta Technology Holdings Limited'>DELT</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a> <font color='red'>-8%</font>. URRE <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/AXAS' title='Abraxas Petroleum Corporation'>AXAS</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/STML' title='Stemline Therapeutics'>STML</a> <font color='red'>-5%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3236389\" data-linked=\"Premarket Gainers / Losers as of 9:10 am\" data-tweet=\"$IDXG $GLBS $WLKP - Premarket Gainers / Losers as of 9:10 am https://seekingalpha.com/news/3236389-premarket-gainers-losers-of-9-10?source=tweet\" data-url=\"https://seekingalpha.com/news/3236389-premarket-gainers-losers-of-9-10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:15 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3236386\" data-ts=\"1484921322\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SWKS\" target=\"_blank\">SWKS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3236386-skyworks-solutions-targets-broadly-raised\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Skyworks Solutions targets broadly raised</a></h4><ul><li><a href=\"http://www.streetinsider.com/Analyst+Comments/Skyworks+Solutions+%28SWKS%29+PT+Raised+to+%24105+at+Drexel+Hamilton/12442680.html\" target=\"_blank\">Drexel Hamilton</a>&nbsp;(Buy) &ndash; from $90 to $105</li><li><a href=\"http://www.streetinsider.com/Analyst+Comments/Skyworks+Solutions+%28SWKS%29+PT+Raised+to+%2496+at+Canaccord+Genuity/12442855.html\" target=\"_blank\">Canaccord Genuity</a>&nbsp;(Buy) &ndash; from $92 to $96</li><li><a href=\"http://www.streetinsider.com/Analyst+EPS+Change/Skyworks+Solutions+%28SWKS%29+PT+Raised+to+%2492+at+Needham+%26+Company+Following+Solid+1Q+Beat+and+Raise/12442840.html\" target=\"_blank\">Needham &amp; Company</a>&nbsp;(Buy) &ndash; from $84 to $92</li><li><a href=\"http://www.streetinsider.com/Analyst+Comments/Skyworks+Solutions+%28SWKS%29+PT+Raised+to+%2480+at+Mizuho+Securities+As+Inventory+%26+Gross+Margins+%22Underwhelm%22/12442462.html\" target=\"_blank\">Mizuho Securities</a> (Neutral) &ndash; from $75 to $80</li><li><a href=\"http://www.streetinsider.com/Analyst+Comments/Skyworks+Solutions+%28SWKS%29+PT+Raised+to+%2466+at+Morgan+Stanley%2C+Issues+Mia+Culpa+On+Negative+Call+Into+Earnings/12442487.html\" target=\"_blank\">Morgan Stanley</a>&nbsp;(Underweight) &ndash; from $61 to $66</li><li>Skyworks Solutions (NASDAQ:<a href='https://seekingalpha.com/symbol/SWKS' title='Skyworks Solutions, Inc.'>SWKS</a>)&nbsp;<font color='green'>+7.69%</font>&nbsp;pre-market at $84.49.</li><li>Earlier (January 20, 2017):&nbsp;<a href=\"https://seekingalpha.com/news/3236373-brean-capital-reiterates-skyworks-solutions-buy-increases-target-95\" target=\"_blank\">Brean Capital reiterates Skyworks Solutions at Buy, increases target to $95</a>&nbsp;/&nbsp;<a href=\"https://seekingalpha.com/news/3236371-cowen-company-raises-skyworks-solutions-target-85-reiterates-market-perform\" target=\"_blank\">Cowen and Company raises Skyworks Solutions target to $85, reiterates Market Perform</a></li><li>Previously (January 19, 2017): <a href=\"https://seekingalpha.com/news/3236191-skyworks-solutions-plus-6_42-percent-q1-strong-500m-buyback-authorized\" target=\"_blank\">Skyworks Solutions +6.42%; Q1 strong, $500M buyback authorized</a>&nbsp;/&nbsp;<a href=\"https://seekingalpha.com/news/3236276-qorvo-cirrus-logic-gain-subsequent-skyworks-solutions-q1-reporting\" target=\"_blank\">Qorvo, Cirrus Logic gain subsequent Skyworks Solutions' Q1 reporting</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3236386\" data-linked=\"Skyworks Solutions targets broadly raised\" data-tweet=\"$SWKS - Skyworks Solutions targets broadly raised https://seekingalpha.com/news/3236386-skyworks-solutions-targets-broadly-raised?source=tweet\" data-url=\"https://seekingalpha.com/news/3236386-skyworks-solutions-targets-broadly-raised\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3236375\" data-ts=\"1484920346\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CNCE\" target=\"_blank\">CNCE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3236375-concert-pharmas-ctpminus-656-orphan-drug-for-cystic-fibrosis-shares-up-8-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Concert Pharma&#39;s CTP-656 an Orphan Drug for cystic fibrosis; shares up 8% premarket</a></h4><ul><li>Thinly traded micro cap Concert Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/CNCE' title='Concert Pharmaceuticals, Inc.'>CNCE</a>) is up&nbsp;<font color='green'>8%</font>&nbsp;premarket, albeit on only 1,170 shares, in response to its <a href=\"https://seekingalpha.com/pr/16719069-concert-pharmaceuticals-receives-fda-orphan-drug-designation-ctpminus-656-treatment-cystic\" target=\"_blank\">announcement </a>that the FDA has designated Phase 2-stage CTP-656 an Orphan Drug for the treatment of cystic fibrosis. Among the benefits of Orphan Drug status is a seven-year period of market exclusivity in the U.S. for the indication, if approved.</li><li>CTP-656 is a deuterium-modified version of ivacaftor [Vertex Pharmaceuticals' (NASDAQ:<a href='https://seekingalpha.com/symbol/VRTX' title='Vertex Pharmaceuticals Incorporated'>VRTX</a>) Kalydeco] that Concert says has a superior pharmacokinetic profile.</li><li>Results from the Phase 2 study should be available by year-end.</li></ul><div class=\"tiny-share-widget\" data-id=\"3236375\" data-linked=\"Concert Pharma&#39;s CTP-656 an Orphan Drug for cystic fibrosis; shares up 8% premarket\" data-tweet=\"$CNCE $CNCE $VRTX - Concert Pharma&#39;s CTP-656 an Orphan Drug for cystic fibrosis; shares up 8% premarket https://seekingalpha.com/news/3236375-concert-pharmas-ctpminus-656-orphan-drug-for-cystic-fibrosis-shares-up-8-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3236375-concert-pharmas-ctpminus-656-orphan-drug-for-cystic-fibrosis-shares-up-8-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:52 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3236373\" data-ts=\"1484920063\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SWKS\" target=\"_blank\">SWKS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3236373-brean-capital-reiterates-skyworks-solutions-buy-increases-target-to-95\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Brean Capital reiterates Skyworks Solutions at Buy, increases target to $95</a></h4><ul><li>From $85 prior, <a href=\"http://www.streetinsider.com/Analyst+Comments/Skyworks+Solutions+%28SWKS%29+PT+Raised+to+%2495+at+Brean+Capital/12442495.html\" target=\"_blank\">analyst Mike Burton</a>&nbsp;notes: \"The company&rsquo;s strong revenue and EPS performance was due to the new ramps, strong content gains, and design win momentum across its businesses. We continue to like SWKS as we believe the company has one of the best track records for delivering financial performance, an enviable operating profit margin and free cash flow, an above-average growth profile, and a discounted valuation.\"</li><li>Earlier (January 20, 2017): <a href=\"https://seekingalpha.com/news/3236371-cowen-company-raises-skyworks-target-85-reiterates-market-perform\" target=\"_blank\">Cowen and Company raises Skyworks Solutions target to $85, reiterates Market Perform</a></li><li>Previously (January 19, 2017):&nbsp;<a href=\"https://seekingalpha.com/news/3236191-skyworks-plus-6_42-percent-q1-strong-500m-buyback-authorized\" target=\"_blank\">Skyworks Solutions +6.42%; Q1 strong, $500M buyback authorized</a></li><li>Skyworks Solutions (NASDAQ:<a href='https://seekingalpha.com/symbol/SWKS' title='Skyworks Solutions, Inc.'>SWKS</a>)&nbsp;<font color='green'>+7.32%</font>&nbsp;pre-market at $84.20.</li></ul><div class=\"tiny-share-widget\" data-id=\"3236373\" data-linked=\"Brean Capital reiterates Skyworks Solutions at Buy, increases target to $95\" data-tweet=\"$SWKS - Brean Capital reiterates Skyworks Solutions at Buy, increases target to $95 https://seekingalpha.com/news/3236373-brean-capital-reiterates-skyworks-solutions-buy-increases-target-to-95?source=tweet\" data-url=\"https://seekingalpha.com/news/3236373-brean-capital-reiterates-skyworks-solutions-buy-increases-target-to-95\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:47 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3236362\" data-ts=\"1484918074\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HLF\" target=\"_blank\">HLF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3236362-herbalife-preliminary-q4-numbers-on-low-end-of-forecast-shares-down-6-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Herbalife preliminary Q4 numbers on low end of forecast; shares down 6% premarket</a></h4><ul><li>On a preliminary basis, Herbalife (NYSE:<a href='https://seekingalpha.com/symbol/HLF' title='Herbalife Ltd.'>HLF</a>) sees Q4 volume down 1.5% and sales down 4 - 6%. Non-GAAP EPS should be within the previously announced range of $0.80 - 1.00.</li><li>Source: Bloomberg</li><li><strong>2017 guidance</strong>: value point growth: 2.0 - 5.0%; net sales growth: 0.3 - 3.3%; EPS: $3.55 - 3.95; non-GAAP EPS: $4.20 - 4.60; currency adjusted non-GAAP EPS: $4.75 - 5.15.</li><li>Shares are off&nbsp;<font color='red'>6%</font>&nbsp;premarket on modestly higher volume.</li><li><a href=\"https://www.sec.gov/Archives/edgar/data/1180262/000119312517013649/d322807dex991.htm\" target=\"_blank\">Corporate presentation</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3236362\" data-linked=\"Herbalife preliminary Q4 numbers on low end of forecast; shares down 6% premarket\" data-tweet=\"$HLF - Herbalife preliminary Q4 numbers on low end of forecast; shares down 6% premarket https://seekingalpha.com/news/3236362-herbalife-preliminary-q4-numbers-on-low-end-of-forecast-shares-down-6-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3236362-herbalife-preliminary-q4-numbers-on-low-end-of-forecast-shares-down-6-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>36&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3236345\" data-ts=\"1484916930\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BMY\" target=\"_blank\">BMY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3236345-goldman-says-bristol-myers-opdivo-yervoy-in-front-line-lung-cancer-not-dead-yet-shares-down-7\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Goldman says Bristol-Myers&#39; Opdivo/Yervoy in front-line lung cancer not dead yet; shares down 7% premarket</a></h4><ul><li>Bristol-Myers Squibb (NYSE:<a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a>) is off&nbsp;<font color='red'>7%</font>&nbsp;premarket on average volume in response to yesterday's <a href=\"https://seekingalpha.com/pr/16718895-bristol-myers-squibb-provides-regulatory-update-first-line-lung-cancer\" target=\"_blank\">announcement </a>that it will not seek accelerated approval of the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) for the first-line treatment of lung cancer [competitor Merck (NYSE:<a href='https://seekingalpha.com/symbol/MRK' title='Merck & Co Inc.'>MRK</a>) is up&nbsp;<font color='green'>4%&nbsp;</font>premarket].</li><li>Goldman Sachs says Bristol's announcement doesn't necessarily mean the end of its effort to develop the combo for lung cancer. It says the company did not take an interim look at the data and the Data Monitoring Committee did not recommend to stop the trial (the company based its decision on a \"review of currently available data\").</li><li>Goldman believes the interim analysis will occur in later this year with a potential regulatory filing in Q4. Its valuation models assume the launch of the combo by 2018, with $1B in sales in first-line lung cancer by 2020 (with a 25% risk adjustment). It adds that Bristol's current price reflects no value for Opdivo in lung cancer and any weakness represents a buying opportunity.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3236296-bristol-myers-will-pursue-accelerated-approval-opdivo-lung-cancer\" target=\"_blank\">Bristol-Myers will not pursue accelerated approval of Opdivo for lung cancer</a> (Jan. 19)</li></ul><div class=\"tiny-share-widget\" data-id=\"3236345\" data-linked=\"Goldman says Bristol-Myers&#39; Opdivo/Yervoy in front-line lung cancer not dead yet; shares down 7% premarket\" data-tweet=\"$BMY $BMY $MRK - Goldman says Bristol-Myers&#39; Opdivo/Yervoy in front-line lung cancer not dead yet; shares down 7% premarket https://seekingalpha.com/news/3236345-goldman-says-bristol-myers-opdivo-yervoy-in-front-line-lung-cancer-not-dead-yet-shares-down-7?source=tweet\" data-url=\"https://seekingalpha.com/news/3236345-goldman-says-bristol-myers-opdivo-yervoy-in-front-line-lung-cancer-not-dead-yet-shares-down-7\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>36&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3236350\" data-ts=\"1484916476\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NGL\" target=\"_blank\">NGL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3236350-ngl-energy-partnersplus-4-on-upward-distribution-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NGL Energy Partners +4% on upward distribution guidance</a></h4><ul><li>NGL&nbsp;Energy Partners (NYSE:<a href='https://seekingalpha.com/symbol/NGL' title='NGL Energy Partners LP'>NGL</a>) <font color='green'>+4.3%</font> premarket after announced <a href=\"https://seekingalpha.com/news/3236281-ngl-energy-partners-declares-0_39-dividend\" target=\"_blank\">flat distributions</a> of $0.39/share for FQ3, to $0.50 for FQ4, and 10% annual growth for three years  thereafter.</li><li>NGL says it will continue to maintain target distribution coverage of 1.3x-1.5x distributable cash flow.</li><li>Based on improved expectations for distribution growth, FBR upgrades shares to Outperform from Market Perform with a $29 price target.</li></ul><div class=\"tiny-share-widget\" data-id=\"3236350\" data-linked=\"NGL Energy Partners +4% on upward distribution guidance\" data-tweet=\"$NGL - NGL Energy Partners +4% on upward distribution guidance https://seekingalpha.com/news/3236350-ngl-energy-partnersplus-4-on-upward-distribution-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3236350-ngl-energy-partnersplus-4-on-upward-distribution-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3236335\" data-ts=\"1484914795\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PG\" target=\"_blank\">PG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3236335-procter-gambleplus-2-after-margins-impress\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Procter &amp; Gamble +2% after margins impress</a></h4><ul>     <li>Procter &amp; Gamble (NYSE:<a href='https://seekingalpha.com/symbol/PG' title='The Procter & Gamble Company'>PG</a>) <a href=\"https://seekingalpha.com/pr/16718992-p-and-g-announces-second-quarter-earnings\" target=\"_blank\">reports</a> organic sales increased 2% in Q4 off a 2% gain in volume during the period. The impact of pricing and mix was flat.</li>     <li>Sales growth by segment: Beauty -1% to 2.942B, grooming -1% to $1.789B, health care +5% to $2.072B, fabric &amp; home care -1% to $5.270B, baby/feminine/family care -1% to $4.645B.</li>     <li>The company says gross margin was 51.5% of sales. Operating profit margin came in at 23.5% of sales.</li>     <li>P&amp;G paid out an effective tax rax rate of 21.3% in Q4.</li>     <li>Opearting cash flow was $3.0B for the quarter. An adjusted free cash flow productivity rate of 82% was reported.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3236327-procter-and-gamble-beats-0_02-beats-revenue\" target=\"_blank\">Procter &amp; Gamble beats by $0.02, beats on revenue</a> (Jan. 20)</li>     <li>PG <font color='green'>+1.92%</font> premarket to $86.33.</li>      </ul><div class=\"tiny-share-widget\" data-id=\"3236335\" data-linked=\"Procter &amp; Gamble +2% after margins impress\" data-tweet=\"$PG - Procter &amp; Gamble +2% after margins impress https://seekingalpha.com/news/3236335-procter-gambleplus-2-after-margins-impress?source=tweet\" data-url=\"https://seekingalpha.com/news/3236335-procter-gambleplus-2-after-margins-impress\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3236333\" data-ts=\"1484914616\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PSTI\" target=\"_blank\">PSTI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3236333-pluristem-increases-underwriting-deal-wainwright-to-15m-shares-down-17-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pluristem increases underwriting deal with Wainwright to $15M; shares down 17% premarket</a></h4><ul><li>Pluristem Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/PSTI' title='Pluristem Therapeutics, Inc.'>PSTI</a>) <a href=\"https://seekingalpha.com/pr/16718994-pluristem-increases-previously-announced-bought-deal-offering-common-stock-warrants-15000-000\" target=\"_blank\">amends </a>its underwriting agreement with H.C. Wainwright to increase its \"bought deal\" offering to $15M. Under the bought deal arrangement, Wainwright will purchase the entire offering of 12,244,898 common shares at $1.225. It will also receive warrants to purchase up to 7,346,939 common shares at $1.40. Gross proceeds will be $15M.</li><li>Wainwright also has a 30-day option to buy up to an additional 1,836,735 common shares with/or warrants to purchase 1,102,041 shares of common. If exercised in full, gross proceeds will be $17.25M.</li><li>Wainwright will sell the equity as Units, each consisting of one common share and 0.6 of a warrant.</li><li>Net proceeds will fund R&amp;D, clinical trial activities, investment in capital equipment, working capital and general corporate purposes.</li><li>Shares are off&nbsp;<font color='red'>17%</font>&nbsp;premarket on increased volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3236333\" data-linked=\"Pluristem increases underwriting deal with Wainwright to $15M; shares down 17% premarket\" data-tweet=\"$PSTI - Pluristem increases underwriting deal with Wainwright to $15M; shares down 17% premarket https://seekingalpha.com/news/3236333-pluristem-increases-underwriting-deal-wainwright-to-15m-shares-down-17-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3236333-pluristem-increases-underwriting-deal-wainwright-to-15m-shares-down-17-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3236332\" data-ts=\"1484914523\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CUBE\" target=\"_blank\">CUBE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3236332-cubesmartminus-1_25-baml-pulls-buy-rating\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CubeSmart -1.25% as BAML pulls Buy rating</a></h4><ul><li>New supply, renter fatigue, and a peak in occupancy have BofA analyst Juan Sanabria cautious on the self-storage REITs in 2017. For CubeSmart (NYSE:<a href='https://seekingalpha.com/symbol/CUBE' title='CubeSmart Common Shares'>CUBE</a>) in particular, Sanabria notes slowing NYC growth combined with exposure to other high supply markets.</li><li>He downgrades to Neutral from Buy, and cuts the price target to $28 from $30.</li><li>Shares&nbsp;<font color='red'>-1.25%</font>&nbsp;premarket to $25.30.</li><li>Source: <a href=\"http://thefly.com/permalinks/entry.php/id2491453/CUBE-CubeSmart-rating-change-at-BofAMerrill\" target=\"_blank\">TheFly</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3236332\" data-linked=\"CubeSmart -1.25% as BAML pulls Buy rating\" data-tweet=\"$CUBE - CubeSmart -1.25% as BAML pulls Buy rating https://seekingalpha.com/news/3236332-cubesmartminus-1_25-baml-pulls-buy-rating?source=tweet\" data-url=\"https://seekingalpha.com/news/3236332-cubesmartminus-1_25-baml-pulls-buy-rating\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3236315\" data-ts=\"1484911237\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EMES\" target=\"_blank\">EMES</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3236315-emerge-energyplus-6_3-on-bullish-call\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Emerge Energy +6.3% on bullish call</a></h4><ul>     <li>Goldman boosts Emerge Energy Services (NYSE:<a href='https://seekingalpha.com/symbol/EMES' title='Emerge Energy Services LP'>EMES</a>) to Buy from Neutral.</li>     <li>PT of $20 implies <font color='green'>36%</font> upside.</li>     <li>Says the market for frac sand is tightening quicker than expected, and EMES is emerging as the marginal supplier.</li>     <li>Notes EMES is down 90% from 2014 peak, vs. -21% for peers.</li>     <li>Moves 2018 EPS estimate to $1.58 from $0.52.</li><li>Says distributions could restart in 2018 or 2019.</li>     <li>EMES is <a href=\"https://twitter.com/germantrader71/status/822398115802071041\" target=\"_blank\">highly shorted</a> (~5 trading days).</li><li>EMES is <font color='green'>+6.3%</font> premarket.</li><li>In the same note, Goldman downgrades Smart Sand (NASDAQ:<a href='https://seekingalpha.com/symbol/SND' title='Smart Sand'>SND</a>) to Neutral from Buy, noting shares have gained 75% since its Nov. 4 IPO. Price target of $17 implies <font color='red'>12%</font> downside. Firm sees potential customer risk from WFT and EOG, notes that the recent RICE contract offers some cushion.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3236315\" data-linked=\"Emerge Energy +6.3% on bullish call\" data-tweet=\"$EMES $EMES $SND - Emerge Energy +6.3% on bullish call https://seekingalpha.com/news/3236315-emerge-energyplus-6_3-on-bullish-call?source=tweet\" data-url=\"https://seekingalpha.com/news/3236315-emerge-energyplus-6_3-on-bullish-call\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":51,"message":null,"success":true,"today":{"start":1576990800,"end":1577077199,"str":"Sunday, December 22, 2019"},"yesterday":{"start":1576904400,"end":1576990799}}